1, Avenue

De Lafayette Boston,

MA,

USA,

ZIP: 02111

Phone: +442031418700

With investment into the Treg field at an all time high, excitement is overflowing at the prospect of these remarkable cells being game-changers in the long-term treatment of autoimmunity, inflammation and transplantation. As this enthusiasm coincides with multiple clinical readouts and several more therapies entering the clinic, it remains vital for Treg trailblazers to come together to recognize therapy efficacy, determine safety and translate the next-generation of therapies into the clinic.  

The Treg Summit returns for the 5th year to unite this dedicated community of industry and academic experts, and remains the go-to industry forum to advance both cell and non-cell based approaches to unlock the potential of Tregs to treat indications with huge unmet clinical need. 

With 3 jam-packed days of content across CAR-, TCR- and polyclonal Tregs as well as IL-2, muteins and small molecules, you won't want to miss this unrivalled opportunity to collaborate with your peers in the Treg field to explore clinical advances, discuss challenges and discover next-gen methods to take Treg therapies to the next level. 

URLs:
Tickets: https://go.evvnt.com/1558199-2?pid=1052
Brochure: https://go.evvnt.com/1558199-3?pid=1052

Prices:
Drug Developer - Conference + Bootcamp Day: USD 4946.00,
Drug Developer - Conference Only: USD 2999.00,
Academic - Conference + Bootcamp Day: USD 4246.00,
Academic - Conference Only: USD 2599.00,
Standard - Conference + Bootcamp Day: USD 6046.00,
Standard - Conference Only: USD 3799.00

Speakers: Ali Zarrin, Vice President and Head of Discovery, TrexBio, Alison Budelsky, Head of Immunology Discovery, Eli Lilly, Anish Suri, President and Chief Scientific Officer, Cue Biopharma, Bertolt Kreft, Chief Scientific Officer, Bright Peak Therapeutics, Dan Mandell, Chief Executive Officer and Co-Founder, GRO Biosciences, David Klatzmann, Professor, Sorbonne University, David Zemmour, Assistant Professor of Pathology, Zemmour Lab, University of Chicago, Denise Faustman, Associate Professor, Harvard Medical School, Diane Mathis, Professor of Immunology, Harvard Medical School, Dirk Brockstedt, Chief Scientific Officer, RAPT Therapeutics, Eliane Piaggio, Scientific Co-founder and Chief Scientific Officer, Egle Therapeutics, Ethan Shevach, Chief, Cellular Immunology Section, NIH/NIAID, Fanny Chapelin, Assistant Professor, Department of Biomedical Engineering, University of Kentucky, Haining Huang, Chief Scientific Officer, Sorrento Therapeutics Inc., Heth Turnquist, Associate Professor, University of Pittsburgh School of Medicine, Hye-Jung Kim, Distinguished Scientist, Genentech, James Mathew, Professor, Northwestern University Feinberg School of Medicine, Jeff Bluestone, Chief Executive Officer and President, Sonoma Biotherapeutics, Jennifer Towne, Vice President, Immunology Discovery and External Innovation, Janssen, Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences, Leonard Dragone, Chief Medical Officer, Sonoma Biotherapeutics, Marc Martinez-Llordella, Co-founder and Vice President, Biology, Quell Therapeutics, Melanie Kleinschek, Chief Scientific Officer, TrexBio, Michelle Higgin, Chief Operating Officer, Slate Bio, Mojca Skoberne, Entrepreneur In Residence, GV, Niranjana Nagarajan, Vice President - Research, Abata Therapeutics, Piotr Trzonkowski, Chief Executive Officer, Poltreg, Rahul Sharma, Chief Scientific Officer, Slate Bio, Raphael Clynes, Vice President - Translational Biology, Xencor, Roly Foulkes Chief Scientific Officer, Revolo Biotherapeutics, Tom Wickham, Chief Scientific Officer, GentiBio, Tracey Lodie, Chief Scientific Officer, Quell Therapeutics, Uli Bialucha, Chief Scientific Officer, Xilio Therapeutics, Zohreh Amoozgar, Principal Scientist and Head of Lab, Sanofi